Brief: Achieve Life Sciences Announces Positive Phase 2 Orca-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit For Participants Treated With Cytisinicline

Achieve Life Sciences

20/04/2023 13:03

April 20 (Reuters) - Achieve Life Sciences Inc  ACHV.O :
    * ACHIEVE LIFE SCIENCES ANNOUNCES POSITIVE PHASE 2 ORCA-V1
TRIAL
RESULTS SHOWING STATISTICALLY SIGNIFICANT VAPING CESSATION
BENEFIT FOR PARTICIPANTS TREATED WITH CYTISINICLINE
    * ACHIEVE LIFE SCIENCES INC - VAPING CESSATION RATE DURING
WEEKS
9-12 WAS 31.8% FOR CYTISINICLINE COMPARED TO 15.1% FOR PLACEBO
    * ACHIEVE LIFE SCIENCES INC - BENEFIT IN FAVOR OF
CYTISINICLINE
WAS CONSISTENTLY OBSERVED ACROSS SECONDARY ENDPOINTS IN PHASE 2
ORCA-V1 TRIAL
    * ACHIEVE LIFE SCIENCES INC - CYTISINICLINE WAS WELL
TOLERATED AND
NO SERIOUS ADVERSE EVENTS WERE REPORTED
    * ACHIEVE LIFE SCIENCES - SIMILAR RATES OF ADVERSE EVENTS
WERE
OBSERVED BETWEEN TREATMENT ARMS IN PHASE 2 ORCA-V1 TRIAL
    * ACHIEVE LIFE SCIENCES - PLANS TO ANNOUNCE TOPLINE RESULTS
IN Q2
2023 FROM PHASE 3 ORCA-3 TRIAL FOR CYTISINICLINE AS A NEW
SMOKING CESSATION TREATMENT

Source text for Eikon:  ID:nGNX6DGmLc 
Further company coverage:  ACHV.O